

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 Oct 2021

### Effects of Taurine Powder Supplementation on Inflammatory Markers and Clinical Outcomes in Traumatic Brain Injury Patients Admitted to the Intensive Care Unit

#### Protocol summary

IL-6, IL-10, TNF-a, hs-CRP, weight,disease severity, malnutrition,Time of connecting to the ventilator

#### Study aim

Determination of the effects of supplementation of Taurine powder on inflammatory markers and clinical implications in patients with traumatic brain injury admitted to the intensive care unit

#### Design

This study is a clinical trial randomized, double blind and parallel, will be carried out on 44 patients with traumatic brain injury,who are eligible for inclusion criteria and admitted to the intensive care unit of Golestan Hospital in Ahvaz. Patients are randomly divided into two groups.

#### Settings and conduct

this study is a double-blind clinical trial with the aim of evaluating the effect of taurine powder supplementation on inflammatory markers and clinical outcomes in traumatic brain injury patients admitted to intensive care unit at Golestan Hospital, Ahvaz. Neither patients nor the investigator are aware of the fact of receiving or not receiving Taurin, and the gavage of patients is prepared by a third person. Patients at the beginning and at the end of the study are taking 10 ml of venous blood to determine serum levels of IL-6, IL-10, TNF-a and hs-CRP.

#### Participants/Inclusion and exclusion criteria

At least 18 years old, Patients with traumatic brain injury with GCS = 6-12, receiving enteral nutrition. The patient should not be pregnant or breastfeeding, lack of liver or kidney disorders, The patient has not received anti-inflammatory drugs or corticosteroids before entering the study. lack of congenital amino acid disorder. More than 60% of energy and protein requirements are calculated during the first week by enteral nutrition.

#### Intervention groups

Intervention: Standard Gavage powder for Karen pharma and taurine powder with a dose of 30 mg /kg body weight divided in two doses for 14 days Control : Standard Gavage powder for Karen pharma for 14 days

#### Main outcome variables

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180514039657N1**

Registration date: **2018-06-22, 1397/04/01**

Registration timing: **registered\_while\_recruiting**

Last update: **2018-06-22, 1397/04/01**

Update count: **0**

##### Registration date

2018-06-22, 1397/04/01

##### Registrant information

##### Name

mahsa vahdat

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 61 3373 8253

##### Email address

vahdat.m@ajums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-06-10, 1397/03/20

##### Expected recruitment end date

2019-01-10, 1397/10/20

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty  
**Trial completion date**  
empty

**Scientific title**  
Effects of Taurine Powder Supplementation on Inflammatory Markers and Clinical Outcomes in Traumatic Brain Injury Patients Admitted to the Intensive Care Unit

**Public title**  
effects of taurine in traumatic brain injury

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

At least 18 years old GCS=6-12 traumatic brain injury patients receive enteral nutrition

**Exclusion criteria:**

Taking anti-inflammatory drugs or corticosteroids before entering the study Patients with liver or kidney disorders Pregnant or lactating women Patients with Congenital Amino Acid Metabolism Disorder Failure to provide more than 60% of the energy and protein requirement calculated through enteral nutrition in the first week

**Age**  
From **18 years** old

**Gender**  
Both

**Phase**  
2-3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: **44**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
Assignment of patients to each groups is done by random block method using block of size 6. In order to ensure that the selection bias does not occur, the allocation method is used to allocate a unique code to each patient.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
the type of blinding in our study is double-blind. Taurine powder is dissolved by an individual except the researcher in the gavage solution and is coded as A and B, so that the investigator will not be informed of the patient's receipt or not of Taurine. Patients are randomly allocated to each group A and B.

**Placebo**  
Not used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

**Ethics committee**

**Name of ethics committee**

Ethics committee of Ahvaz University of Medical Sciences

**Street address**

Vice Chancellor for Research and Technology, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd, Ahvaz

**City**

ahvaz

**Province**

Khuzestan

**Postal code**

61357-15794

**Approval date**

2018-01-27, 1396/11/07

**Ethics committee reference number**

IR.AJUMS.REC.1396.919

## Health conditions studied

### 1

**Description of health condition studied**

traumatic brain injury

**ICD-10 code**

S06.2

**ICD-10 code description**

Diffuse traumatic brain injury

## Primary outcomes

### 1

**Description**

high sensitive C-Reactive Protein

**Timepoint**

The beginning and end of the study

**Method of measurement**

ELISA

### 2

**Description**

Tumor Necrosis Factor-alpha

**Timepoint**

The beginning and end of the study

**Method of measurement**

ELISA

### 3

**Description**

Interleukin-6

### **Timepoint**

The beginning and end of the study

### **Method of measurement**

ELISA

### **4**

#### **Description**

Interleukin-10

#### **Timepoint**

The beginning and end of the study

#### **Method of measurement**

ELISA

### **5**

#### **Description**

weight

#### **Timepoint**

The beginning and end of the study

#### **Method of measurement**

Patient bedside scale

### **6**

#### **Description**

Clinical outcome measurement

#### **Timepoint**

day 1,7,14

#### **Method of measurement**

Sequential Organ Failure Assessment(SOFA) score

### **7**

#### **Description**

disease severity

#### **Timepoint**

day 1,14

#### **Method of measurement**

APACHEII score

## **Secondary outcomes**

### **1**

#### **Description**

30-day mortality

#### **Timepoint**

day 30

#### **Method of measurement**

Contact with patient's family

### **2**

#### **Description**

length of stay to ICU

#### **Timepoint**

daily

#### **Method of measurement**

observation

### **3**

#### **Description**

malnutrition

#### **Timepoint**

The beginning and end of the study

#### **Method of measurement**

subjective global assessment

### **4**

#### **Description**

Dependence on ventilator

#### **Timepoint**

daily

#### **Method of measurement**

Counting the number of ventilator attachment days

## **Intervention groups**

### **1**

#### **Description**

Intervention group: standard entrameal of karen pharma with taurine powder with a dose 30 mg/kg in two divided doses per day for 14 days

#### **Category**

Treatment - Drugs

### **2**

#### **Description**

Control group: standard entrameal of karen pharma for 14 days

#### **Category**

Treatment - Drugs

## **Recruitment centers**

### **1**

#### **Recruitment center**

##### **Name of recruitment center**

Ahvaz Golestan Hospital

##### **Full name of responsible person**

mahsa vahdat

##### **Street address**

Ahvaz Golestan hospital, Golestan Blvd, Ahvaz

##### **City**

ahvaz

##### **Province**

Khouzestan

##### **Postal code**

6135733118

##### **Phone**

+98 61 3374 3001

##### **Email**

vahdat.m@ajums.ac.ir

## **Sponsors / Funding sources**

## 1

### Sponsor

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Mohammad Badavi

**Street address**

Vice Chancellor for Research and Technology, Ahvaz  
Jundishapur University of Medical Sciences, Golestan  
Blvd, Ahvaz

**City**

ahvaz

**Province**

Khouzestan

**Postal code**

61357-15794

**Phone**

+98 61 3336 7570

**Email**

badavi-m@ajums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Ahvaz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Mahsa Vahdat

**Position**

Msc Student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

Faculty of Paramedicine, Jundishapur University of  
Medical Sciences

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

6135815751

**Phone**

+98 61 3321 4578

**Email**

vahdat.m@ajums.ac.ir

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Seyyed Ahmad Hosseini

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Paramedical School, Ahvaz Jundishapur University of  
Medical Sciences, Golestan Blvd, Ahvaz

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

61357-15794

**Phone**

+98 61 3333 3050

**Email**

seyedahmadhosseini@yahoo.com

### Person responsible for updating data

**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Mahsa Vahdat

**Position**

Msc Student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

Faculty of Paramedicine, Jundishapur University of  
Medical Sciences

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

6135815751

**Phone**

+98 61 3321 4578

**Email**

vahdat.m@ajums.ac.ir

### Sharing plan

#### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

If the decision is to publicate the data, after the unidentified individuals all data will be publicated.

**When the data will become available and for how long**

The access period will be 6 months after the publication of the results.

**To whom data/document is available**

Researchers working in academic and industrial institutions can apply to get data.

**Under which criteria data/document could be used**

To cite. Referring to reference or researcher's permission

**From where data/document is obtainable**

Mahsa Vahdat. Faculty of Paramedicine, Jundishapur University of Medical Sciences, Golestan Blvd, Ahvaz. vahdat.m@ajums.ac.ir

**What processes are involved for a request to access data/document**

Access to articles related to this research. Send email to the responsible author

**Comments**